Pyxis Oncology Inc reports results for the quarter ended in December - Earnings Summary

Pyxis Oncology

22/03/2024 12:02

* Pyxis Oncology Inc  PYXS.OQ  reported a quarterly adjusted
loss
of 33 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-1.01.  The mean expectation of six analysts
for the quarter was for a loss of 47 cents per share. Wall
Street expected results to range from -57 cents to -35 cents per
share.
    * Reported revenue was zero​; analysts expected $166.67
thousand. 
    * Pyxis Oncology Inc's reported EPS for the quarter was a
loss
of 33 cents​.
    * The company reported a quarterly loss of $15.6 million.
    * Pyxis Oncology Inc shares had risen by 175.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 6.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Pyxis Oncology
Inc is $7.50 
This summary was machine generated from LSEG data March 22 at
12:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.47          -0.33          Beat
 Sep. 30 2023      -0.51          -0.56          Missed
 Jun. 30 2023      -0.65          -0.41          Beat
 Mar. 31 2023      -0.90          -0.55          Beat